Аlexandr I. Kirienko

Аlexandr I. Kirienko

Auto-generated profile, based on publicly available information

Аlexandr I. Kirienko

Department of Faculty Surgery, Pirogov Russian National Research Medical University, Moscow, Russia

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
ASA. Shadrina
A. Shadrina
YTYakov Tsepilov
Yakov Tsepilov
MSMariya A. Smetanina
Mariya A. Smetanina
EVE. Voronina
E. Voronina
ESE. Seliverstov
E. Seliverstov
MFM. Filipenko
M. Filipenko

25 September 2017 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
ASA. S. Shadrina
A. S. Shadrina
MSMariya A. Smetanina
Mariya A. Smetanina
KSK. S. Sevost’yAnova
K. S. Sevost’yAnova
ASA. I. Shevela
A. I. Shevela
ESE. I. Seliverstov
E. I. Seliverstov
MFM. L. Filipenko
M. L. Filipenko

1 November 1980 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
VSV. S. Savelyev
V. S. Savelyev
EYE. G. Yablokov
E. G. Yablokov
AKA. I. Kirienko
A. I. Kirienko
SSS. V. Savelyev
S. V. Savelyev

1 January 2016 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
AKA. I. Kirienko
A. I. Kirienko
YSYu. N. Shevtsov
Yu. N. Shevtsov
ANA. S. Nikishkov
A. S. Nikishkov
ESE. I. Seliverstov
E. I. Seliverstov
AAA. V. Andriyashkin
A. V. Andriyashkin
IZI. A. Zolotuhin
I. A. Zolotuhin
Издательство Медиа Сфера - 25 медицинских журналов общим тиражом около 500 000 экземпляров в год, представлены в международных базах данных Scopus, Medline, и Google Scolar, включены в перечень изданий ВАК, представлены в РИНЦ

14 August 2018 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
AKA. Kirienko
A. Kirienko
DRD. Radak
D. Radak
AMA. Maggioli
A. Maggioli
Aim: To investigate the clinical efficacy of micronized purified flavonoid fraction (MPFF) 1000 mg given as a single 1000 mg tablet once daily in patients suffering from chronic venous disease (CVD) vs MPFF 500 mg twice daily. Methods: In an international, randomized, double-blind, parallel-group study, patients classified C0s to C4 according to Clinical Etiological Anatomic Pathophysiologic [CEAP] classification and with leg pain graded as superior to 4 cm on a 10-cm visual analog scale (VAS), were treated for 8 weeks with either MPFF 1000 mg once daily or MPFF 500 mg twice daily. The present post-hoc analysis focuses on the effect of treatment over time in patients randomized to the MPFF 1000 mg group. Leg pain was assessed at each follow-up visit by VAS. VAS scores over time were compared between each visit using paired Student t-tests. Results: In total, 87 patients out of 174 were randomized to the MPFF 1000 mg group. Mean age ± SD was 49.1 ± 12.2 years, most of the patients were female (81.6%), the main CEAP classes of the most affected leg were C1 (20.7%), C2 (39.1%), C3 (33.33%), and the mean duration of CVD was 14.6 ± 10.9 years. Patients with previous CVD treatment represent 27.6% of the patients. A MPFF 1000 mg tablet once daily was associated with a significant and continuous reduction in leg pain throughout the treatment period: –1.54 cm (±1.45) from baseline to week 2 (p < .01), –1.11 cm (±1.06) from week 2 to week 4 (p < .01), –1.57 cm (±1.05) from week 4 to week 8 (p < .01). Conclusions: The new MPFF 1000 mg dose regimen in once daily tablets was associated with a rapid and continuous reduction in leg pain throughout the 8-week treatment period.